April 14, 2021
Mayo Clinic and AI-driven health technology company nference launched Anumana, Inc.™ to create and commercialize innovative digital sensor diagnostics by harnessing industry-leading AI and clinically-driven insights that decipher electrocardiograms (ECGs) in ways never before possible. Anumana will initially focus on designing and bringing to market state-of-the-art neural network algorithms based on billions of relevant pieces of heart health data in Mayo Clinic's Clinical Data Analytics Platform, including millions of raw ECG signals, unlocking hidden biomedical knowledge aimed at enabling early detection of heart disease and accelerating treatments. Anumana makes it possible to see signs of illness that were once invisible and predict disease before specific symptoms appear, empowering healthcare providers, accelerating patient treatments, reducing costs and enhancing quality of life.
“Signs of illness are often invisible, even to the most trained eye. Now, for the first time, we will make it possible to see them,” said Murali Aravamudan, CEO of nference and Anumana. “Our deep learning neural networks, in the hands of scientific and clinical experts, will enable a comprehensive translation of the language of the heart. We think of it as the Rosetta Stone for cardiac medicine.”
We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to firstname.lastname@example.org